The Global Bioprocess Validation Market Growth Accelerated By Validation Techniques
The global Bioprocess
Validation Market is estimated to be valued at US$ 411.04 Mn in 2023 and is
expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031, as
highlighted in a new report published by Coherent Market Insights.
Market key trends
Technological advancements in bioprocess validation is one of the major trends
driving growth of the bioprocess validation market. Key players are focusing on
developing innovative techniques and tools to streamline validation processes
and technologies for continuous bioprocessing. For instance, in 2021,
3DBiomatrix introduced a range of bioreactor technology including single-use
bioreactors to facilitate continuous and automated validation of
biomanufacturing processes. The company’s novel bioreactor technology helps
accelerate product development cycles and reduce validation timelines through
continuous process monitoring and control. Such developments are expected to
positively impact the adoption of bioproces
s validation techniques over the
forecast period.
Segment Analysis
The global bioprocess validation market is dominated by the upfront segment.
This is because upfront validation is required to be performed before the
production of biotherapeutics to ensure product quality and purity. It accounts
for over 60% of the market share as comprehensive testing and documentation is
required as per regulatory guidelines prior to the commercial production of
biologic drugs and therapies.
Key Takeaways
The global Bioprocess
Validation Market Demand is expected to witness high growth over the
forecast period of 2024 to 2031 supported by increasing demand for biologics
and stringent regulatory norms governing their production. The global
Bioprocess Validation Market is estimated to be valued at US$ 411.04 Mn in 2023 and is
expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031.
Regional analysis: North America currently dominates the global market and is
expected to maintain its leading position throughout the forecast period. High
biopharmaceutical research activities in the US and rising production of
advanced biologics drive the North American market. The Asia Pacific region is
projected to be the fastest growing market attributed to increasing investments
by major players, rising contract research and manufacturing activities in
countries like China and India.
Key players: Key players operating in the bioprocess validation market are GSK
Plc (U.K.), TheraVida (U.S.), Revance (U.S.)., NovaMedica. (Russia), Ulthera,
Inc. (U.S.), DEMIRA e.V (Germany), Abbvie, Inc (U.S.), Fresh Tracks
Therapeutics, Inc. (U.S.), Dr. August Wolff GmbH (Germany), Dermavant Sciences,
Inc. (U.S.), Eirion Therapeutics, Inc (U.K.). These players are focusing on new
product launches, facility expansions and acquisitions to strengthen their
market position.
Explore more
related article on this topic: https://www.ukwebwire.com/biopharmaceutical-industry-is-driving-the-bioprocess-validation-market/
https://techaxen.com/game-engines-powering-the-future-of-gaming/

Comments
Post a Comment